Clinical Trial: Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma
Study Status: NOT_YET_RECRUITING
Recruit Status: NOT_YET_RECRUITING
Condition: Relapsed Cancer
Study Type: INTERVENTIONAL
Official Title: A Phase II Study of ISABELA: Isatuximab, Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
Brief Summary:
The main goal of this phase II study is to evaluate the overall response rate of isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma.The study drugs provided for research purposes are isatuximab and belantamab mafodotin.
Read more